Impact of adverse drug reactions (ADR) on systemic therapy in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

Marschner, N., Münch, A., Blumenstengel, K., Sauer, U., Müller, L., 2010.

Ann Oncol, Abstract 949 21(suppl 8), viii298. doi:10.1093/annonc/mdq525

Studie: TNK; Indikation: Nierenzellkarzinom; Jahr: 2010; Veranstaltung: ESMO; Journal: Annals of Oncology

iOMEDICO AG
Ellen-Gottlieb-Straße 19
79106 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com